Epifriedelanol acetate [2259-07-6]
Referentie NB-64-64516-5mg
Formaat : 5mg
Merk : Neo Biotech
Epifriedelanol acetate
Catalog No. TN3968 Copy Product Info
Epifriedelanol exhibits antibacterial activities. It also can reduce cellular senescence in human primary cells and may be used to develop dietary supplements or cosmetics that modulate tissue aging or aging-associated diseases. Epifriedelanol and friedelin possess promising antioxidant activity, and they are active against the two cancer cells (human T4 lymphoblastoid (CEM-SS) and human cervical (HeLa) cancer cells) with IC50 values ranging from 3.54 to11.45 ug/ml.
Epifriedelanol acetate
Copy Product InfoEpifriedelanol exhibits antibacterial activities. It also can reduce cellular senescence in human primary cells and may be used to develop dietary supplements or cosmetics that modulate tissue aging or aging-associated diseases. Epifriedelanol and friedelin possess promising antioxidant activity, and they are active against the two cancer cells (human T4 lymphoblastoid (CEM-SS) and human cervical (HeLa) cancer cells) with IC50 values ranging from 3.54 to11.45 ug/ml.
Cas No. 2259-07-6
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Epifriedelanol exhibits antibacterial activities. It also can reduce cellular senescence in human primary cells and may be used to develop dietary supplements or cosmetics that modulate tissue aging or aging-associated diseases. Epifriedelanol and friedelin possess promising antioxidant activity, and they are active against the two cancer cells (human T4 lymphoblastoid (CEM-SS) and human cervical (HeLa) cancer cells) with IC50 values ranging from 3.54 to11.45 ug/ml. |
| Molecular Weight | 470.77 |
| Formula | C32H54O2 |
| Cas No. | 2259-07-6 |
| Smiles | C[C@@]12[C@@]3([C@](C)([C@]4([C@](C)(CC3)[C@@H](C)[C@@H](OC(C)=O)CC4)16)CC[C@@]1(C)[C@]5([C@@](C)(CC2)CCC(C)(C)C5)16)16 |
| Relative Density. | no data available |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |